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Abstract
Background
Undiagnosed infections accounted for the hidden proportion of HIV cases that have
escaped from public health surveillance. To assess the population risk of HIV transmission,
we estimated the undiagnosed interval of each known infection for constructing the HIV inci-
dence curves.
Methods
We used modified back-calculation methods to estimate the seroconversion year for each
diagnosed patient attending any one of the 3 HIV specialist clinics in Hong Kong. Three
approaches were used, depending on the adequacy of CD4 data: (A) estimating one’s pre-
treatment CD4 depletion rate in multilevel model;(B) projecting one’s seroconversion year
by referencing seroconverters’ CD4 depletion rate; or (C) projecting from the distribution of
estimated undiagnosed intervals in (B). Factors associated with long undiagnosed interval
(>2 years) were examined in univariate analyses. Epidemic curves constructed from esti-
mated seroconversion data were evaluated by modes of transmission.
Results
Between 1991 and 2010, a total of 3695 adult HIV patients were diagnosed. The undiag-
nosed intervals were derived from method (A) (28%), (B) (61%) and (C) (11%) respectively.
The intervals ranged from 0 to 10 years, and were shortened from 2001. Heterosexual infec-
tion, female, Chinese and age >64 at diagnosis were associated with long undiagnosed
interval. Overall, the peaks of the new incidence curves were reached 4–6 years ahead of
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reported diagnoses, while their contours varied by mode of transmission. Characteristically,
the epidemic growth of heterosexual male and female declined after 1998 with slight
rebound in 2004–2006, but that of MSM continued to rise after 1998.
Conclusions
By determining the time of seroconversion, HIV epidemic curves could be reconstructed
from clinical data to better illustrate the trends of new infections. With the increasing cover-
age of antiretroviral therapy, the undiagnosed interval can add to the measures for assess-
ing HIV transmission risk in the population.
Introduction
Before progression to AIDS, HIV infection is largely asymptomatic in the period since serocon-
version, the duration of which can be as long as 7 years or more in the absence of treatment.[1]
An HIV-infected individual remains undiagnosed, unless he/she receives an HIV test for differ-
ent reasons. Within this undiagnosed period, infected individuals are not aware of their HIV
status. Their transmission risk can be substantial in the presence of a high partner exchange
rate and the practice of unprotected sex. After HIV diagnosis, transmission risk may fall as a
result of self-initiated reduction of risk behaviours and/or interventions.[2] Moreover, good
coverage of highly active antiretroviral treatment (HAART) could reduce the population viral
burden, thereby minimizing the transmission risk, as concluded in the HPTN052 study.[3, 4]
Therefore, the status of being undiagnosed, the first stage of the care continuum cascade, con-
stitutes a major gap for achieving effective interventions through HAART. Epidemiologically,
the lag time between infection and diagnosis is an obstacle for proper interpretation of epi-
demic curves plotted by annual numbers of new HIV diagnoses, as recent and past infections
could not be differentiated. Quantification of the undiagnosed intervals is, therefore instru-
mental for reconstructing epidemic curves for supporting the effective monitoring of the epi-
demic and evaluating interventions introduced.
In the past, HIV incidence back-calculated by computing the number of diagnosed AIDS
cases and distribution of incubation period between HIV infection and AIDS diagnosis[5] was
a reasonable approach. The widespread use of HAART since the mid-1990s has however dis-
torted the natural history of HIV/AIDS. While a few studies have introduced modified back-
calculation method that incorporated diagnosed HIV cases,[6] the estimation of new infections
was often made at aggregate level. Other studies have used biological approaches such as tests
for recent infection (TRIs), recent infection testing algorithm (RITA) and BED HIV-1 Capture
Enzyme Immunoassay to determine whether a diagnosed individual was recently infected.[7,
8] However, such method was limited by the availability of samples, technologies and
resources, and could only broadly distinguish between recent and non-recent infections. To
date, some studies have estimated the prevalence of undiagnosed HIV-infected individuals and
investigated their epidemiological characteristics, as reported in China,[9] India,[10] Spain,
Italy, Slovakia, Romania, Slovenia and Czech Republic.[11] While these studies have provided
insights into the size of the hidden infective populations, temporal patterns were not systemati-
cally evaluated.
At an individual level, the undiagnosed interval has largely been ignored so far, except for a
limited number of studies which computed seroconverters’ pre-treatment CD4 depletion rate
to back-calculate the year of seroconversion,[12, 13] or used diagnosed individuals’ specific
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test-seeking behaviours and clinical status at diagnosis to estimate the time interval between
infection and diagnosis.[14, 15] Against these backgrounds, we propose to expand the modified
back-calculation method to make full use of currently available clinical data to determine the
undiagnosed interval for each HIV positive individual, using seroconverters’ CD4 depletion as
the reference group With this approach, we estimated the seroconversion year and undiag-
nosed interval at individual level and reconstructed the HIV incidence curves to help explain
the temporal trend of virus transmission in the city of Hong Kong.
Methods
Data source
In Hong Kong, 3 HIV specialist clinics in the public service are providing care to almost all
reported HIV/AIDS cases in the territory, the data from which constituted the cohort database
described in this study.[16] HAART is initiated in accordance with local guidelines adapted
from the recommendations of Department of Health and Human Services in USA.[17] Demo-
graphics, baseline clinical conditions and regularly collected laboratory measures (CD4 and
viral load) in 1985–2012 were accessed. Approvals from the Research Ethics Committee of the
Joint Chinese University of Hong Kong—New Territories East Cluster, and Kowloon Central/
Kowloon East Cluster of the Hospital Authority were obtained. In compliance with the Per-
sonal Data (Privacy) Ordinance, data access was approved by the Department of Health, Hong
Kong Special Administrative Region Government. No informed consent was obtained as the
collected data were anonymized and collected retrospectively. This study was conducted in
compliance with Declaration of Helsinki.
Modified back-calculation methods for estimating seroconversion year
In our study, the annual number of new infections, total number of undiagnosed infections, and
every HIV infected person’s undiagnosed interval were derived after estimating the seroconver-
sion year individually. Estimation was made by the modified back-calculation approach, taking
reference from the pre-treatment CD4 trajectory of known HIV-infected patients. As a set-point
viral load is reached about 6 months after infection,[1] this interval was deducted from the time-
point when CD4 count reaches a plateau following acute infection. According to the number of
pre-treatment CD4 measurements in the clinical dataset, patients were classified into Group A
(>3 CD4 counts), Group B (1–3 CD4 counts) and Group C (no CD4 count) for the estimation.
Group A (individuals with>3 pre-treatment CD4 counts). Methodologically, if over 3
pre-treatment CD4 counts have been recorded, the levels were input in multilevel model (lme4
R package) to derive the pre-treatment CD4 depletion rate for each patient. Linear multilevel
model was performed because of the repeated CD4 measurements available per patient.[18] In
the model, CD4 measurements (outcome variable) were nested by patients, with time (defined
as months from the first CD4 measurement after diagnosis) as random intercept and random
slope, and ethnicity and gender as random intercepts. The seroconversion year of HIV patients
who were infected via injection drug use or sexual transmission were estimated separately in
multilevel model. Different combination of variables in multilevel model were explored and
the best multilevel model was selected with reference to intraclass correlation coefficient (ICC).
[19] By randomly selecting a CD4 count within the normal reference range of a healthy adult
for 1000 times,[20–22] and using these as the starting points for CD4 depletion, the serocon-
version year of a patient was calculated in Eq 1 [23, 24] for 1000 simulations:
seroconversion year ¼ diagnosis year þ random normal CD4 reference rangei;j  a
monthly CD4 slope  12 ð1Þ
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Where i is gender (male, female), j is ethnicity (1. Asian, 2. White, 3. African & others),[20–22]
a is intercept of an individual’s regression line in multilevel model, CD4 slope is the adjusted
coefficient of the individual’s regression line in multilevel model
The simulation results falling outside the lower boundary (a. the last negative HIV testing
year; or b. 1980, which might be the year with the first possible infection case in Hong Kong; or
c. year of attaining 12 year-old, possible minimum age of being sexually active) and the upper
boundary (year of HIV diagnosis) were discarded.
We have selected the pre-treatment CD4 counts of seroconverters (patients with2 years’
time interval from last negative HIV test to first positive HIV test) to form a reference dataset
to validate the simulation results. Their CD4 measurements were input to the same multilevel
model as patients in Group A, with the removal of the year of last negative HIV testing date as
the lower boundary of filter. The simulation results were compared with the mid-point of the
interval between the last negative and the first positive HIV tests, assuming the latter method
gave the most precise estimation.[25] The seroconversion time of patients in Group A was
derived from the third quartile of the simulation results as these were closest to the mid-point
estimation by comparison. (S1 Table) The discrepancy would be the smallest if we take the
90th percentile, but this would not be meaningful unless everyone had seroconverted a year
before diagnosis.
Group B (individuals with 1–3 pre-treatment CD4). Multilevel models were performed
in a different way for patients with 1–3 CD4 measurements before treatment initiation, or if
Group A estimation failed due to minimal changes in CD4 count pre-treatment or rising pre-
treatment CD4 count with slope of depletion above -1/μL/month. Reference range of coeffi-
cients showing the relationship between seroconversion time (mid-point of interval between
last negative and first positive HIV testing2 years) and CD4 count was first established from
seroconverters in the same cohort. The seroconversion year of injection drug users (IDU) and
sexually acquired HIV patients were estimated separately by linear multilevel model. Time
(months from seroconversion time) and ethnicity (being White or not) were random intercepts
in the model. Gender was not included in the selected multilevel model as it was not signifi-
cantly associated with CD4 count. With the coefficients determined in multilevel model, the
year of seroconversion was estimated by:
CD4measurement year  CD4  random intercept  coefficient White
12random CD4 slope ð2Þ
The randomly generated intercept and coefficient were derived from the mean and standard
deviation of coefficients calculated in multilevel model. A total of 2500 simulations were per-
formed for a clinical measurement available. As the seroconversion time of patients in Group
A were estimated by the third quartile of simulation result, the same logic applied here.
Group C (individuals without pre-treatment CD4 count). For individuals without pre-
treatment CD4 count or with flat or rising pre-treatment CD4 slope (above -1/μL/month), esti-
mation of seroconversion year was made from the estimation results of Group B. This was
based on the distribution of estimated undiagnosed interval (from year of seroconversion to
diagnosis) in patients in Group B, as the in care condition between the two Groups were simi-
lar, both with less frequent or irregular visit to the clinics before treatment. Due to their similar-
ity, the seroconversion year was calculated by subtracting the median undiagnosed interval
from the year of diagnosis, stratified by mode of transmission and status of late HIV diagnosis.
(Table 1) Late HIV diagnosis here refers to the diagnosis of AIDS within 3 months of HIV
diagnosis. Sensitivity analyses were performed to examine the difference of seroconversion esti-
mation results between selection of reference groups 1) Group A, 2) Group B and 3) Group A
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and B that were used to derive undiagnosed intervals, and selection of central tendency
(a. median, b. first quartile and c. third quartile) of undiagnosed intervals.
Analyses. With the estimation of seroconversion year at individual level, we plotted the
HIV incidence curves as the yearly estimated count of individuals who had seroconverted. The
annual number of undiagnosed individuals were plotted as the total number of HIV-infected
remaining undiagnosed in the respective year. Undiagnosed interval was defined as the differ-
ence between year of seroconversion and year of diagnosis. The temporal trend of diagnosed,
newly diagnosed, newly infected and undiagnosed were smoothed in 2-year windows by Sea-
sonal-Trend Decomposition Procedure based on Loess in R3.2.2.[26] Associations between
characteristics of patients and undiagnosed interval>2 years were examined in univariate
analyses. We examined the confounding effects of ethnicity (Chinese vs non-Chinese), gender
(female vs male), age at diagnosis (continuous variable) and mode of transmission (MSM vs
non-MSM) in multivariable logistic regression models in SPSS. Confounding variables affect-
ing>10% change of crude odds ratio (OR) of other independent variables were kept in the
model for calculating adjusted odds ratio (aOR) of other independent variables. Patients were
selected for analysis if they were diagnosed in 1991–2010, during which a CD4-guided
approach was the norm for treatment initiation. We also used an alternative approach to esti-
mate seroconversion time in sensitivity analysis. First, we estimated the seroconversion time
with the original method proposed in this study. Second, we used Group B method to estimate
the seroconversion time for patients with any pre-treatment CD4 counts (i.e. patients in Group
A and Group B), while Group C method for Group C patients. Third, we used Group C
method to estimate the seroconversion time for all patients. Lastly, we took the average undiag-
nosed interval among the 3 estimations for each patient, and performed univariate analysis to
examine the association between long undiagnosed interval and independent variables.
Results
As of 2012, 74,541 clinical measurements of 4551 HIV patients have been collected, of which
data from 3695 adult (aged 18 or older) HIV patients diagnosed in 1991–2010 were selected for
inclusion in the study. The sample size accounted for about 80% of diagnosed HIV cases
recorded in the surveillance system during the 20-year period. Among them, 27% (999/3695)
were in late HIV diagnosis, and 14% (528/3695) were seroconverters with an interval2 years
between last HIV negative testing date and first HIV positive testing date. The seroconversion
year of each case was estimated, of which 1050 (28%) were in Group A, 2241 (61%) in Group B
and 404 (11%) in Group C.
Table 1. Summary for median of intervals between HIV diagnosis year and 3rd quartile of the simulation results of seroconversion year in Group B
patients.
Subgroups by transmission route Median of interval (year) n Median of interval (year) n
Non-late diagnosis Late diagnosis*
Blood recipient 1 39 1 8
Heterosexual female 2 333 3 166
Heterosexual male 2 518 3 499
Injection drug use 2 148 2 35
Men who have sex with men 2 739 3 295
Undetermined 3 37 4 31
*Late diagnosis—patients diagnosed with AIDS within 3 months of HIV diagnosis
doi:10.1371/journal.pone.0159021.t001
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Multilevel model results
Linear multilevel models were performed to estimate pre-treatment CD4 depletion rate in both
Group A and Group B. There was high heterogeneity of CD4 depletion rate among patients,
with ICC ranging between 51% and 89% (Table 2). In Group A, the CD4 depletion rate of
patients who contracted HIV through sexual contact (n = 831 patients) and contaminated needle
sharing (n = 95 patients) were similar at around –5 cells/μL per month from baseline. Among
individuals infected through sexual contact, the White were adjusted to have higher CD4 (82.7/
μL) than their counterparts. In Group B, pre-treatment CD4 depletion rate among seroconver-
ters infected through sexual contact (n = 347 patients) was similar to those in Group A. However,
the CD4 depletion rate of IDU seroconverters (n = 8 patients) was lower (- 2/μL) than those in
Group A. The third quartile of simulation results in Group A and Group B are shown in S1 Fig.
Trends of annual number of new infections and undiagnosed infections
Compared with the annual new diagnoses, the peak of new infections occurred 4–6 years in
advance (Fig 1). The peak for new heterosexual male and female infections was reached in
1996–1998, followed by a decline in 1998–2004. The rebound of new heterosexual male infec-
tions after 2004 on the newly constructed curve contrasted significantly with the plateauing of
the reported incidence curve from 1998 onward. The annual total number of undiagnosed het-
erosexual male and female was at least two-folds that of new diagnoses in 1995–2007. The esti-
mated proportion of undiagnosed individuals dropped linearly from 52% in 1996 to 16% in
2006 among heterosexual male, and from 60% to 20% in among heterosexual female.
For men-who-have-sex-with-men (MSM), the epidemic curves were distinctly different
between new infections and new diagnoses. (Fig 1) Following a steady increase in the 1980s
and 1990s, rapid upsurge of new infections could be seen in 1998–2001, six years in advance of
Table 2. Pre-treatment CD4 depletion rate in cells/month estimated in the linear multilevel models for patients in Group A and Group B.
sexually acquired infections infections in IDU
Group A
Dataset for multilevel model: CD4 data of patients with >3 pre-treatment CD4 count
Sample size 8398 CD4 counts in 831 patients 728 CD4 counts in 95 patients
ICC 86% 89%
Random effect
Months from baseline CD4 variance = 13.4, SD = 3.7 variance = 4.5, SD = 2.1
Fixed effect
Months from baseline CD4 coe: -5.0 (s.e. = 0.16, t-value = -0.7) coe: -4.2 (s.e. = 0.4. t-value = -11.9)
Being White coe: 82.7 (s.e. = 28.6, t-value = 2.9) /
Group B
Dataset for multilevel model: CD4 data of seroconverters
Sample size 2971 CD4 counts in 347 patients 72 CD4 counts in 8 patients
ICC 84% 51%
Random effect
Months from seroconversion variance = 17.8, SD = 4.2 variance = 0.3, SD = 0.5
Fixed effect
Months from seroconversion coe: -4.7 (s.e. = 0.3. t-value = -15.2) coe: -2.2 (s.e. = 0.5. t-value = -4.6)
Being White coe: 73.5 (s.e. = 30.1, t-value = 2.4) /
ICC (intraclass correlation coefficient) = intercept variance / (intercept variance + residual variance) [19] coe-coefficient, s.e.-standard error
doi:10.1371/journal.pone.0159021.t002
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Fig 1. Annual number of reported new diagnoses and prevalent cases (number of diagnosed HIV-
infected cases who were alive), estimated new infections and undiagnosed infections (total number
of infections remaining undiagnosed) with uncertainty intervals smoothed by Seasonal-Trend
Decomposition Procedure based on Loess for (a) heterosexual male, (b) MSM, (c) heterosexual
female and (d) IDU.
doi:10.1371/journal.pone.0159021.g001
HIV Incidence Estimation
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the new diagnoses curve. After a drop in 2001–2004, the MSM epidemic rose again, as shown
by the increasing number of new infections. The annual number of undiagnosed MSM was at
least twice that of the new diagnoses in 1995–2007, with a widening difference after 1999. The
estimated proportion of undiagnosed MSM dropped and became stable at 32%-43% in 1996–
2006. The contours of the injection drug users’ (IDU) curves for new infections, new diagnoses
and undiagnosed were similar, with a rise followed by a decline. There was however an earlier
peak for the former (2003 vs 2007). Similar to the heterosexuals, the proportion of undiagnosed
IDU fell from 56% in 1996 to 27% in 2006.
In the sensitivity analyses, the difference between annual number of new infections using
different reference groups (Group A, Group B, or Group A and B) for estimating seroconver-
sion year in Group C were minimal (Fig 2). The contours of new infection curves using differ-
ent measures (first quartile, median and third quartile) from the 3 groups of patient data were
largely similar, though the specific time of rise and fall varied.
Undiagnosed interval
The interquartile range of estimated undiagnosed intervals was 1–4 years (range: 0–10 years).
The proportion of short undiagnosed intervals (2 years) increased across time. Also, the
Fig 2. Sensitivity analysis of new infection curves constructed by computing the first quartile, third quartile andmedian of the
simulation results in Group A and B, and the median of undiagnosed interval in reference group (Group A, Group B, Group A and
B) for Group C, by mode of transmission.
doi:10.1371/journal.pone.0159021.g002
HIV Incidence Estimation
PLOS ONE | DOI:10.1371/journal.pone.0159021 July 12, 2016 8 / 15
distribution of estimated undiagnosed intervals varied both by the estimation methods and
mode of transmission. Higher variation of undiagnosed interval was observed in Group A than
the other two groups. (Fig 3a) The proportion of longer undiagnosed interval was higher in
Group B than those in Group A, while the proportion in Group C was the lowest. By mode of
transmission, the first quartile of undiagnosed interval in MSM was much shorter than that of
heterosexual male and female. (Fig 3b) The interquartile range of undiagnosed intervals was at
least 3 years in MSM after 1999, while the high variation of intervals among heterosexual male
and female patients was seen in 2000–2001 only.
Dichotomizing the undiagnosed intervals by a threshold of 2 years, two groups (>2 years vs
2 years) were compared (Table 3). Patients with longer undiagnosed interval were more likely
to have contracted HIV through heterosexual contact (OR = 1.61, 95%C.I. = 1.42–1.84), be
female (OR = 1.20, 95%C.I. = 1.02–1.43), of Chinese ethnicity (OR = 1.29, 95%C.I. = 1.12–
1.49), and age>64 at diagnosis (OR = 2.96, 95%C.I. = 2.05–4.26, aged35 as reference group).
At diagnosis, they were more likely to have higher baseline viral load (>log10 5 copies/mL)
Fig 3. A) Temporal variation of the proportion of undiagnosed intervals (years) and the seroconversion
estimation methods applied. B) Yearly variation of undiagnosed intervals (years) by mode of transmission.
doi:10.1371/journal.pone.0159021.g003
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(aOR = 1.25, 95%C.I. = 1.07–1.47) and to be in late HIV diagnosis (aOR = 2.87, 95%C.I. =
2.45–3.37), after adjusting for age at diagnosis, being MSM and Chinese. Adjusted by the same
confounders, clinically, they were more likely to have initiated HAART (aOR = 1.82, 95%C.I. =
1.54–2.14), and be diagnosed with AIDS (aOR = 1.95, 95%C.I. = 1.69–2.25). In the sensitivity
analysis, factors associated with undiagnosed interval>2 years as shown in S2 Table were simi-
lar to results in Table 3, but gender was no longer significantly associated.
Discussion
In this study, we estimated the seroconversion time of individual HIV-infected adults to recon-
struct the epidemic curves for Hong Kong, an approach that managed to remove the influence
of the highly varied patterns of HIV diagnoses. Compared to a previous local study which used
a modified back-calculation method at population level for estimating HIV incidence,[6] our
incidence curve showed a similar epidemiologic trend with their estimated curve, but our curve
ran 4–5 years ahead of theirs. Apart from the different sources and characteristics of data for
estimation, the variation of parameters used could be another reason of discrepancy. In our
study, we used pre-treatment CD4 depletion rates to back-calculate the year of seroconversion,
while the previous local study was parametrized by the lengths of incubation period, settings of
diagnosis (routine testing and symptom-related testing) and the annual number of HIV diag-
noses and AIDS diagnoses.[6] Elsewhere, back-calculation of the seroconversion year with
CD4 depletion rate has been applied,[12, 13, 15] though most had used the depletion rate of
seroconverters as reference group. The latter was adopted as one of the three approaches for
estimation in this study. Another approach was applied for patients with very comprehensive
CD4 reference data, while a third approach was adopted for patients without any pre-treatment
CD4 count. Our mixed-methods approach for estimation illustrated the complexity of data
availability in reality, reflecting that a single method might not be able to solve all problems.
Our estimated pre-treatment CD4 depletion rate was 56/μL—60/μL per year for sexually
acquired HIV infections, which was consistent with the estimated range for patients from
Europe and Australia.[27]
Apart from showing an earlier peak in the incidence curves compared to new diagnoses
curves, it is noted that the contour of the epidemic curves varied remarkably by the route of
HIV transmission. Instead of a continuous rise in the number of newly diagnosed MSM
through 2010, our seroconversion curve peaked in 2000–2001, followed by a temporal decline
in 2001–2004, and then rose back to the 2001 level. With the increasing number of undiag-
nosed MSM in the community, the number of newly diagnosed MSM was expected to rise sig-
nificantly and continuously. However, the observed increase was relatively modest. This could
be partly explained by the relatively short undiagnosed interval in HIV-infected MSM. The
transmission risk tended to fall after diagnosis as a result of behavioural changes [2] and viral
load suppression following HAART.[4] The trend was also consistent with the relatively stable
HIV prevalence of MSM reported at different time-points in Hong Kong in 2006, 2008 and
2011.[28]
The epidemic growth for heterosexually acquired infection was very different. The total
number of undiagnosed HIV infected heterosexuals increased in 1996–2002, followed by a
slower growth afterwards. Unlike MSM, HIV-infected heterosexuals were more likely to have
longer undiagnosed interval. This might be partly due to the high proportion of non-locally
acquired heterosexual infections,[29] and could also be a result of their different partnership
pattern. A Taiwan study on Chinese heterosexual partnership showed that many (around 56%)
were in serial monogamy [30], implying on-going transmission could be limited. When a het-
erosexual person is infected with HIV, virus transmission might occur to affect 1 or 2 sex
HIV Incidence Estimation
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Table 3. Characteristics of HIV-infected patients with long (>2 years) undiagnosed interval from estimated seroconversion to HIV diagnosis, com-
pared to patients with a shorter interval.
Undiagnosed interval
2 years (n = 1929)
Undiagnosed interval >2
years (n = 1766)
Crude Odds Ratio (OR) Adjusted Odds Ratio (aOR)‡
no. % no. % OR 95% CI aOR 95% CI
Demographics
Gender
Male 1612 53% 1428 47% ref
Female 317 48% 338 52% 1.20 1.02–1.43*
Ethnicity
Non-Chinese (Asian, White, others, NA) 593 57% 452 43% ref
Chinese 1336 50% 1314 50% 1.29 1.12–1.49*
Mode of transmission
Non-heterosexuals (MSM, IDU, BL and UN) 1036 58% 739 42% ref
Heterosexuals 893 47% 1027 53% 1.61 1.42–1.84*
Heterosexual female 298 48% 326 52% ref
Heterosexual male 595 46% 701 54% 1.08 0.89–1.3
Non-MSM (heterosexuals, IDU, BL and UN) 1082 47% 1223 53% ref
MSM 847 61% 543 39% 0.57 0.5–0.65*
Conditions at diagnosis
Age at diagnosis
Aged35 1075 61% 696 39% ref
Aged 36–64 807 45% 980 55% 1.88 1.64–2.14*
Aged >64 47 34% 90 66% 2.96 2.05–4.26*
Baseline VL (copies/mL)
< = log10 5 823 47% 924 53% ref ref
>log10 5 432 40% 660 60% 1.36 1.17–1.59* 1.25 1.07–1.47*
Late HIV diagnosis#
No 1622 60% 1074 40% ref ref
Yes 307 31% 692 69% 3.4 2.92–3.97* 2.87 2.45–3.37*
Treatment
Initiated HAART by 2012
No 552 64% 313 36% ref ref
Yes 1377 49% 1453 51% 1.86 1.59–2.18* 1.82 1.54–2.14*
Time from HAART to SVL
>3 months 783 48% 845 52% ref ref
3 months 606 50% 618 50% 0.94 0.81–1.1 0.97 0.83–1.13
Outcomes
Years with NSVL after diagnosis
< = 3 years 1030 47% 1173 53% ref ref
>3 years 899 60% 593 40% 0.58 0.51–0.66* 0.66 0.57–0.76*
Ever diagnosed with AIDS
No 1387 60% 932 40% ref ref
Yes 542 39% 834 61% 2.29 2–2.62* 1.95 1.69–2.25*
Deceased by 2012
No 1725 54% 1498 46% ref ref
Yes 204 43% 268 57% 1.51 1.25–1.84* 1.03 0.84–1.27
*p-value <0.05
MSM-men who have sex with men, IDU-injection drug use, BL-blood transfusion, UN-undetermined, VL-viral load, HAART- highly active antiretroviral
therapy, SVL-suppressed viral load (500copies/mL), NSVL-non-suppressed viral load (>500copies/mL)
‡adjusted by mode of transmission (MSM vs non-MSM), age at diagnosis (continuous) and ethnicity (Chinese vs non-Chinese) in multivariable logistic
regression model
#Late HIV diagnosis refers to patients diagnosed with AIDS within 3 months of HIV diagnosis
doi:10.1371/journal.pone.0159021.t003
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partners regardless of the length of the undiagnosed interval. This pattern differs considerably
from the dense networking of some MSM, whose HIV infection may be characterised by rapid
growth.[31] While female sex workers (FSW) could form a bridge in intensifying virus spread,
their low HIV prevalence of below 0.2%,[32, 33] means that rapid dissemination from HIV
infected FSW to their clients was unlikely.
For IDU, the flat contour of newly infected IDU lent support to the uncommon occurrence
of local transmission, which could be attributed to the longstanding methadone treatment pro-
gramme introduced since the 1970s.[34] For both heterosexuals and IDU, the epidemic curves
redrawn with estimated seroconversion years ran 4 years in advance of their diagnoses. Evi-
dently, the estimation of new infections has contributed to the assessment of HIV transmission
risk in the population and subpopulations.
The length of undiagnosed intervals carries significant public health implications. Our
study has identified the following associating factors with long undiagnosed interval in Hong
Kong: heterosexual, female, Chinese ethnicity, and age>64 at diagnosis. The longer undiag-
nosed interval in heterosexual male/female and elderly was probably related to their lower per-
ceived risks of infection, compared to younger MSM in the local community, an observation
that has also been made elsewhere.[35] Because of the low perceived risk of infection, HIV test-
ing experiences of heterosexuals, especially the elderly, are predictably low. With 27% of
patients in late HIV diagnosis, expanded HIV testing is therefore one most imminent strategy
for shortening the undiagnosed interval, which can serve not just to improve clinical outcomes
but also reduce transmission risk in the community. An earlier diagnosis of HIV infection is
desirable regardless of the route of transmission. Our results showed that early diagnosis was
negatively associated with high baseline viral load and AIDS diagnosis, adjusted by ethnicity,
mode of transmission and age at diagnosis. Paradoxically, they had a longer duration of non-
suppressed viral load, which was probably due to higher baseline CD4 and therefore longer
interval between diagnosis and treatment initiation, in accordance with the CD4-guided
approach to HAART. Expanded treatment initiation has recently been recommended by
World Health Organization to cover all diagnosed patients with any CD4 count,[36] a strategy
supported by increasing number of clinical studies which would predictably shorten the dura-
tion of non-suppressed viral load if early diagnosis could be achieved. Separately, a meta-analy-
sis study concluded that there was a lower prevalence of risk behaviour after one became aware
of the HIV status.[2] A combination of early diagnosis and universal treatment without regard
to the prevailing CD4 count would predictably reduce the undiagnosed interval and facilitate
the plateauing of the HIV epidemic curves.
We acknowledge that the study carries some limitations. As it takes time to capture a major-
ity of the infected patients in a year, estimation by back-calculation approach was limited to
the use of data before 2008, five years before the end of our data collection period. The estima-
tion for patients in Group C was based on the estimation result in Group B, which might not
be the best reference group to represent patients in Group C. However, from the sensitively
analyses for reference group selections, Group B might be a better option under existing data
availability. Also, in the course of conducting CD4 depletion rate estimation, the small propor-
tion of rapid progressors and long-term non-progressors had been ignored. Their contribution
to the epidemic growth is however predicted to be small. We assumed linear trajectory of pre-
treatment CD4 decline and ignored the association between CD4 and viral load levels. We
acknowledge there exists a wide range of uncertainties in applying our proposed estimation
methods, and there are rooms for improvement in future epidemiologic estimation. Finally, it
may not be easy to have Group Amethod regularly applied as the immediate treatment strategy
is becoming a routine in clinical services. In practice, the future approach might rely more on
Group B and C with additional information such as patients’ perception of their infection date,
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viral load measurement, seroconversion illnesses and molecular study. Nonetheless, we believe
our mixed-methods approach has demonstrated the feasibility of using readily available longi-
tudinal clinical data for epidemiologic estimation.
In conclusion, we have endeavoured to estimate the undiagnosed interval at individual level
with currently available clinical data, without resorting to sophisticated laboratory technolo-
gies, to reconstruct HIV epidemic curves founded on seroconversion time rather than clinical
diagnoses. The study was conducted in a small city where a majority of patients were managed
according to similar clinical guidelines. In principle, a plausible estimation approach can be
adopted, which can be turned into a public health tool for describing and projecting HIV epi-
demiology in places where pre-treatment CD4 data are available from the HIV services.
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